World Conference on Lung Cancer 2022: Updates in NSCLC

home / post-conference-perspectives / world-conference-on-lung-cancer-2022-updates-in-nsclc

Dr Millie Das, MD discusses updates from the 2022 World Conference on Lung Cancer regarding non-small cell lung cancer (NSCLC).

EP. 1: IMpower010 Trial Evaluating Atezolizumab Versus Best Supportive Care (BSC)

September 16th 2022

Dr Millie Das, MD opens a discussion surrounding updates regarding non-small cell lung cancer (NSCLC) as presented at the 2022 World Conference on Lung Cancer (WCLC).

Watch

EP. 2: Evolving NSCLC Treatment Landscape Following IMpower010 Trial Data

September 23rd 2022

IMpower010 trial data may influence a significant evolution in treatment of non–small cell lung cancer.

Watch

EP. 3: Aligning Cost-Effective Payer Strategies With Clinical Pathway Considerations for NSCLC Treatment

September 30th 2022

Millie Das, MD, shares key takeaways from her presentation regarding cost-effective strategies and payer considerations related to the treatment of NSCLC.

Watch

EP. 4: HUDSON Trial Overview and Key Takeaways

October 7th 2022

The HUDSON trial is explored by Dr Das as she provides an overview of the study and offers key considerations regarding results.

Watch

EP. 5: JAVELIN Lung 100 Trial Evaluating Progression-Free and Overall Survival for Patients With NSCLC

October 14th 2022

Millie Das, MD, outlines the JAVELIN Lung 100 trial and shares insights on strategies and data interpretation from the trial.

Watch

EP. 6: Emphasizing Biomarker-Driven Treatment and Individualized Care Strategies for Patients With NSCLC

October 21st 2022

Dr Millie Das, MD discusses updates from the 2022 World Conference on Lung Cancer regarding non-small cell lung cancer (NSCLC).